mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Antidepressant Action of Ketamine: In contrast to the weeks or months of treatment required for standard antidepressant medication, ketamine administration produces an antidepressant response within 4 to 6 hours in depressed patients. What lies behind the rapid actions of ketamine? Li et al. (p. 959 ; see the Perspective by Cryan and O'Leary ) found that ketamine administration resulted in fast activation of mammalian target of rapamycin (mTOR) signaling and increased levels of synaptic proteins in the rat prefrontal cortex. Ketamine rapidly increased the density and function of the dendritic spines of layer V pyramidal neurons in the prefrontal cortex. Thus, the behavioral actions of ketamine in models of depression and antidepressant response are dependent on mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have suggested that ketamine can increase the synthesis of synaptic proteins through BDNF signaling dependent on the activate protein kinase B (Akt) and mammalian target of rapamycin complex 1 (mTORC1) signaling cascades. 378 , 379”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esmethadone can also alleviate neural dysfunction linked to symptoms of depression by boosting the synapse and spine density and restoring spinogenesis, in addition to correcting depressive-like behaviors in animal models of depression. 378 , 477”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine rapidly and transiently increases glutamate transmission in the PFC, possibly via inhibition of tonically active GABAergic inter-neurons, and the resulting burst of glutamate is thought to underlie ketamine induction of synapto-genesis (6, 7).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single dose of ketamine increases BDNF release and stimulates mTORC1 signaling, which leads to increased levels of synaptic proteins (i.e., GluR1, PSD95, and synapsin 1) and increased number and function of synapses in the PFC 4,22,35 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [35]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Functional neuroimaging studies of depression: The anatomy of melancholia
Drevets, W. C. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.341 · Cited by 500
Liu, R.-J., & Aghajanian, G. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706679105 · Cited by 346
Self-citation
Cited by
Items 1,001–1,062 of 1,062
Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action
Ficek, J., Zygmunt, M., Piechota, M., Hoinkis, D., Rodriguez Parkitna, J., Przewlocki, R., & Korostynski, M. (2016) · BMC Genomics · doi:10.1186/s12864-016-2713-3 · Cited by 42
“Ketamine has been shown to induce expression of synapse-associated proteins through the rapid activation of mTOR-regulated ERK and Akt signaling pathways [11].”
Björkholm, C., Jardemark, K., Schilström, B., & Svensson, T. H. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.002 · Cited by 42
Intracellular Signaling Pathways Involved in ( S )- and ( R )-Ketamine Antidepressant Actions
Zanos, P., & Gould, T. D. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.026 · Cited by 42
“Notably, only lower doses of ketamine enhance mTORC1 activity, whereas anesthetic doses of the drug do not influence mTOR signaling, in accordance with the antidepressant actions of the drug, which only occur at lower doses (7).”
BackgroundResultInfluentialKetamine metabolite pilot study in a suicidal depression trial
Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Parris, M. S., Burke, A. K., Suckow, R. F., Cooper, T. B., & Mann, J. J. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.08.005 · Cited by 41
“…2008; Trullas and Skolnick, 1990), and trophic effects via mechanistic target of rapamycin (mTOR) and brain derived neurotrophic factor (BDNF) stimulating or maintaining dendritic spinogenesis (Ardalan et al., 2017; Autry et al., 2011; Duman and Duman, 2015; Li et al., 2010; ModaSava et al., 2019).”
BackgroundWang, N., Zhang, G.-F., Liu, X.-Y., Sun, H.-L., Wang, X.-M., Qiu, L.-L., Yang, C., & Yang, J.-J. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0277-8 · Cited by 41
“The dose of 10 mg/kg to elicit ketamine’s antidepressant effects was selected on the basis of previous studies (Beurel et al. 2011; Li et al. 2010).”
Contribution of NMDA receptors to dorsolateral prefrontal cortical networks in primates
Wang, M., & Arnsten, A. F. T. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-014-1504-6 · Cited by 41
“beneficial effects of ketamine in some patients, prior to the regrowth of dendritic spines([53]) that may underlie more prolonged beneficial actions.”
Electroconvulsive seizures stimulate the vegf pathway via mTORC1
Elfving, B., & Wegener, G. (2012) · Synapse · doi:10.1002/syn.21518 · Cited by 40
“…al., 2011; Sarbassov et al., 2005) and recently, it has been demonstrated that fast activation of mTOR signaling represents a mechanism for the rapid antidepressant effect of ketamine (a glutamate N-methyl-D-aspartic acid (NMDA) receptor antagonist) in prefrontal cortex from rats (Li et al., 2010).”
BackgroundPlasticity of synapses and reward circuit function in the genesis and treatment of depression
Thompson, S. M. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01422-1 · Cited by 40
“Furthermore, co-administration of the mTOR inhibitor rapamycin prevented the induction of dendritic spines by ketamine, as well as ketamine’s actions in the FST and other behaviors [202].”
BackgroundKetamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
Bandeira, I. D., Lins-Silva, D. H., Cavenaghi, V. B., Dorea-Bandeira, I., Faria-Guimarães, D., Barouh, J. L., Jesus-Nunes, A. P., Beanes, G., Souza, L. S., Leal, G. C., et al. (2022) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000330 · Cited by 39
Ketamine prevents stress-induced cognitive inflexibility in rats
Nikiforuk, A., & Popik, P. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.11.009 · Cited by 39
“The activation of mTOR pathway was also involved in ketamine-induced increase in synaptic signalling proteins (Li et al., 2010).”
BackgroundMishra, P. K., Kumar, A., Behar, K. L., & Patel, A. B. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14544 · Cited by 39
“Recent molecular studies in rodents show that ketamine’s antidepressant effects involve activation of the mammalian target of rapamycin pathway and synaptogenesis (Li et al. 2010; Duman et al. 2012).”
BackgroundBortolozzi, A., Manashirov, S., Chen, A., & Artigas, F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107873 · Cited by 37
Russell, T. A., Blizinsky, K. D., Cobia, D. J., Cahill, M. E., Xie, Z., Sweet, R. A., Duan, J., Gejman, P. V., Wang, L., Csernansky, J. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms5858 · Cited by 37
“Additionally, while the sibling carrying the variant did not present with schizophrenia, she had been diagnosed with major depressive disorder, the treatment of which has been linked to increased dendritic spine formation 35 .”
Yang, Y., Song, Y., Zhang, X., Zhao, W., Ma, T., Liu, Y., Ma, P., Zhao, Y., & Zhang, H. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05490-3 · Cited by 36
Witkin, J. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172854 · Cited by 36
Höflich, A., Kraus, C., Pfeiffer, R. M., Seiger, R., Rujescu, D., Zarate, C. A., Kasper, S., Winkler, D., & Lanzenberger, R. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01318-6 · Cited by 34
Kanzari, A., Bourcier-Lucas, C., Freyssin, A., Abrous, D. N., Haddjeri, N., & Lucas, G. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.94 · Cited by 33
Bowman, M. A., Vitela, M., Clarke, K. M., Koek, W., & Daws, L. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207581 · Cited by 33
“Currently this is viewed as the primary mechanism underlying ketamine’s antidepressant-like effects in preclinical studies [8,10].”
BackgroundAverill, L. A., Averill, C. L., Gueorguieva, R., Fouda, S., Sherif, M., Ahn, K.-H., Ranganathan, M., D'Souza, D. C., Southwick, S. M., Sanacora, G., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.01.104 · Cited by 33
Self-citationHow do serotonergic psychedelics treat depression: The potential role of neuroplasticity
Artin, H., Zisook, S., & Ramanathan, D. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i6.201 · Cited by 33
Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors
Sumner, R. L., McMillan, R., Spriggs, M. J., Campbell, D., Malpas, G., Maxwell, E., Deng, C., Hay, J., Ponton, R., Sundram, F., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.07.009 · Cited by 32
Agnieszka, P.-P., Karolina, P., & Andrzej, P. (2019) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000471 · Cited by 31
“First, it has been repeatedly shown that NBQX inhibited the antidepressant-like effects of group II mGlu receptor antagonists as well as the effects of ketamine and its enantiomers and active metabolites in several animal models of depression (Li et al., 2010; Autry et al., 2011; Koike et al., 2011; Koike and Chaki, 2…”
BackgroundRethinking the role of TRKB in the action of antidepressants and psychedelics
Brunello, C. A., Cannarozzo, C., & Castrén, E. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.08.011 · Cited by 31
“However, it remains to be determined whether mTOR is activated downstream or upstream of BDNF/ TRKB signaling [9].”
BackgroundBettini, E., Stahl, S. M., De Martin, S., Mattarei, A., Sgrignani, J., Carignani, C., Nola, S., Locatelli, P., Pappagallo, M., Inturrisi, C. E., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15080997 · Cited by 31
“REL-1017 (esmethadone HCl; dextromethadone HCl), the d-isomer of racemic methadone, is a low-affinity, low-potency, uncompetitive NMDAR channel blocker, devoid of meaningful opioid agonist effects [12] with experimental evidence for producing brain-derived neurotrophic factor (BDNF) and target of rapamycin complex 1 (…”
BackgroundAbdallah, C., Averill, L. A., Gueorguieva, R., Goktas, S., Purohit, P., Ranganathan, M., D'Souza, D. C., Formica, R., Southwick, S. M., Duman, R. S., et al. (2018) · doi:10.1101/500959 · Cited by 30
“Several preclinical studies have shown that ketamine administration increases mTORC1 signaling (10-13), but there are non-replications of this finding (14).”
BackgroundMethodResultSelf-citationYang, C., Li, W.-Y., Yu, H.-Y., Gao, Z.-Q., Liu, X.-L., Zhou, Z.-Q., & Yang, J.-J. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/175619 · Cited by 29
“A recent study has indicated that ketamine’s antidepressant effects are associated with the upregulation of mTOR in prefrontal cortex [12], which is confirmed by a subsequent case report with an increase of mTOR in the peripheral blood in a depressed patient [13].”
BackgroundDe Martin, S., Gabbia, D., Folli, F., Bifari, F., Fiorina, P., Ferri, N., Stahl, S., Inturrisi, C. E., Pappagallo, M., Traversa, S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671859 · Cited by 28
“BDNF production has been implicated in the mechanism of action of antidepressant drugs (Li et al., 2010).”
BackgroundPharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine
Shaffer, C. L., Dutra, J. K., Tseng, W. C., Weber, M. L., Bogart, L. J., Hales, K., Pang, J., Volfson, D., am Ende, C. W., Green, M. E., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.04.019 · Cited by 28
Opler, L. A., Opler, M. G. A., & Arnsten, A. F. T. (2016) · CNS Spectrums · doi:10.1017/s1092852914000686 · Cited by 28
“Although this may be important for longer-term amelioration of TRD, the rapid improvements in depression within minutes cannot be due to the formation of new synapses on spines, as new synapses were only evident after 2 hours, not within minutes.(15) We hypothesize that intranasal ketamine’s ultra-rapid antidepressant…”
BackgroundPsilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628
“Likewise, synaptic deficiencies including loss of dendritic arborization, reduced spine density, and damped neurotransmission are present in the frontal cortex of rodent chronic stress models (Cook and Wellman, 2004; Liston et al., 2006; Radley et al., 2004; Yuen et al., 2012).”
Mikoteit, T., Hemmeter, U., Eckert, A., Brand, S., Bischof, R., Delini-Stula, A., Holsboer-Trachsler, E., & Beck, J. (2015) · Neuropsychobiology · doi:10.1159/000437439 · Cited by 25
Waller, J. A., Chen, F., & Sánchez, C. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.012 · Cited by 25
Grieco, S. F., Qiao, X., Johnston, K. G., Chen, L., Nelson, R. R., Lai, C., Holmes, T. C., & Xu, X. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01255-4 · Cited by 24
Xie, Y.-C., Yao, Z.-H., Yao, X.-L., Pan, J.-Z., Zhang, S.-F., Zhang, Y., & Hu, J.-C. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180782 · Cited by 24
Singh, N. S., Rutkowska, E., Plazinska, A., Khadeer, M., Moaddel, R., Jozwiak, K., Bernier, M., & Wainer, I. W. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149499 · Cited by 23
“This effect was also observed after the administration of (R,S)-Ket and was associated with (R,S)-Ket’s antidepressant activity in the Wistar rat [8,9].”
BackgroundRen, L. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110910 · Cited by 23
“Induction of translation results in increased levels of PSD95, GluA1 and other synaptic proteins, providing the machinery required for increased synaptogensis and spine formation (Li et al., 2010).”
BackgroundInfluentialERK/mTOR signaling may underlying the antidepressant actions of rapastinel in mice
Shen, M., Lv, D., Liu, X., & Wang, C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02290-5 · Cited by 22
Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413658 · Cited by 21
“This inhibitory action subsequently liberates mTOR Complex 1 (mTORC1) from its regulatory constraints. mTORC1 then phosphorylates downstream targets including p70S6K and 4E-BP1 (see Figure 3) [105,143].”
Pérez de la Mora, M., Borroto-Escuela, D. O., Crespo-Ramírez, M., Rejón-Orantes, J. D. C., Palacios-Lagunas, D. A., Martínez-Mata, M. K., Sánchez-Luna, D., Tesoro-Cruz, E., & Fuxe, K. (2022) · Cells · doi:10.3390/cells11111826 · Cited by 21
Ketamine for Depression: An Update
Murrough, J. W. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.005 · Cited by 20
Santos, M., Lima, L., Carvalho, S., Mota-Pereira, J., Pimentel, P., Maia, D., Correia, D., Barroso, M. F., Gomes, S., Cruz, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076758 · Cited by 20
“Several polymorphisms in genes involved in several neurotrophic/neuroplasticity pathways were evaluated, namely BDNF (rs1491850, rs204946, rs6265, rs908867), CREB1 (rs11904814, rs2253206, rs6740584, rs889895), NTRK2 (rs1187323, rs1187326, rs1387926, rs1778929, rs1565445, rs1659412), NGFR (rs11466155, rs2072446, rs7341…”
BackgroundInfluentialNV-5138 as a fast-acting antidepressant via direct activation of mTORC1 signaling
Hasegawa, Y., Zhu, X., & Kamiya, A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129702 · Cited by 20
Serotonin is a common thread linking different classes of antidepressants
Witt, C. E., Mena, S., Holmes, J., Hersey, M., Buchanan, A. M., Parke, B., Saylor, R., Honan, L. E., Berger, S. N., Lumbreras, S., et al. (2023) · Cell Chemical Biology · doi:10.1016/j.chembiol.2023.10.009 · Cited by 18
Ketamine modifies mood through mTOR
Welberg, L. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2916 · Cited by 16
Adler, S. M., Girotti, M., & Morilak, D. A. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2020.100258 · Cited by 15
Comparison of Antidepressant‐Like and Abuse‐Related Effects of Phencyclidine in Rats
Hillhouse, T. M., Porter, J. H., & Negus, S. S. (2014) · Drug Development Research · doi:10.1002/ddr.21228 · Cited by 15
“Furthermore, ketamine produced sustained (>24 h pretreatment time) antidepressant-like effects in the forced swim test and chronic unpredictable stress procedure [Maeng et al., 2008; Li et al., 2010; Autry et al., 2011; Gigliucci et al., 2013].”
BackgroundDonello, J. E., McIntyre, R. S., Pickel, D. B., & Stahl, S. M. (2025) · Pharmaceuticals · doi:10.3390/ph18020157 · Cited by 15
“…be related to BDNF– protein eukaryotic role for this shown to stimulate other downstream signaling pathways, such as extracellular-regulated protein kinase (ERK), mammalian target of rapamycin (mTOR), and glycogen synthase kinase 3, all of which have been implicated in synaptogenesis [33,39,75,76].”
Chen, M., Jin, J., Bi, H., Zhang, Y., Sun, M., Li, X., & Wang, Y. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104502 · Cited by 14
Self-citationBarnett (2024) · doi:10.1089/psymed.2023.0010 · Cited by 13
“12,124 Enhanced structural plasticity in the neocortex has been observed with a single dose of psilocybin, an effect that does not seem to be effectively blocked with ketanserin (a 5-HT 2A receptor antagonist).”
Asch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
The NMDA receptor subunit GluN2D is a potential target for rapid antidepressant action
Vestring, S., Veleanu, M., Perez, M. C., Schuberth, L. E., Bronnec, M., Li, A., Würz, L. M., Erdogdu, F., Stocker, J., Moos, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66774-w · Cited by 13
“KET rapidly upregulates the phosphorylated and activated forms of both p-AKT and p-ERK 61 .”
Classical conditioning of antidepressant placebo effects in mice
Krimmel, S. R., Zanos, P., Georgiou, P., Colloca, L., & Gould, T. D. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05347-4 · Cited by 12
Wegman-Points, L., Pope, B., Zobel-Mask, A., Winter, L., Wauson, E., Duric, V., & Yuan, L.-L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.590221 · Cited by 12
“Interestingly, the antidepressant effect is not seen with anesthetic doses of ketamine in mice[8].”
BackgroundThe metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
(2023) · International Review of Neurobiology · doi:10.1016/bs.irn.2022.10.007 · Cited by 8
Qiao, J., Sun, Y., Wu, J., & Wang, L. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7633 · Cited by 8
“Normal 7 (6,1) 12 (5,7) 8 (8,0) 2 (1,1) 50 (36,14) 91 (47,44) 64 (47,17) 26 (23,3)”
BackgroundBærentzen, S. L., Waszkiewicz, A. L., Thomsen, M., Knudsen, C., Elfving, B., & Landau, A. M. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104079 · Cited by 7
“Data are presented as % of saline. increasing dendritic spine density within 12 – 24 h of administration (Li et al., 2010; Liu et al., 2013; Moda-Sava et al., 2019).”
Wang, S., Li, K., He, Q., Yang, H., Yang, Y., Wang, X., Shu, Y., & Ding, J. (2025) · Epilepsia · doi:10.1111/epi.18498 · Cited by 4
“35,36 To sub-stantiate that neuronal hyperexcitation originates from the excessive dendritic spines and that this mechanism is dependent on mTOR signaling, we applied rapamycin to suppress the activity of mTOR pathway.”
Senserrich, J., Castro, E., Florensa-Zanuy, E., Díaz, Á., Pazos, Á., Adell, A., Tzinia, A., & Pilar-Cuéllar, F. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00716-5 · Cited by 2
“Protein extraction was performed according to the protocol previously described by Li et al. [41].”
From psychache to neuroplasticity: A unified rescue-repair model of Ketamine’s anti-suicidal action
Domany, Y., & Solomon-Shashua, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106804 · Cited by 2
Corvo, C., Goutal, S., Mendez-David, I., Leterrier, S., Caille, F., Saba, W., Colle, R., Corruble, E., Lebon, V., Bottlaender, M., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-025-03369-3 · Cited by 1
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
(2018) · Europe PMC (PubMed Central)
Metadata
- Authors
- Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S.
- Affiliations
- Yale University (US)
- Laboratory of Molecular Psychiatry, Center for Genes and Behavior, Departments of Psychiatry and Neurobiology, Yale University School of Medicine, 34 Park Street, New Haven, CT 06508, USA.
- Corresponding author
- Duman, Ronald S.
- Venue
- Science
- Published
- 2010-08-20
- Volume
- 329
- Issue
- 5994
- Pages
- 959-964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3116441
- OpenAlex
- W2089351762
- Cited by
- 2,881
- References
- 14
- Citations by year
- 2026: 147 · 2025: 161 · 2024: 171 · 2023: 175 · 2022: 218 · 2021: 234 · 2020: 233 · 2019: 202 · 2018: 199 · 2017: 171 · 2016: 205 · 2015: 217 · 2014: 136 · 2013: 153 · 2012: 125
- FWCI
- 96.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute of Mental Health (2P01 MH25642, MH-45481, P01MH025642, R01MH045481)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, mTOR signaling, synaptogenesis, NMDA receptor antagonists, rapid antidepressant effects, treatment-resistant depression, prefrontal cortex, dendritic spines, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Male, Neurons, Neuropeptides, Phenols, Piperidines, Synapses, Time Factors, Protein Biosynthesis, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Rats, Sprague-Dawley, Protein Serine-Threonine Kinases, Sirolimus, Intracellular Signaling Peptides and Proteins, Dendritic Spines, Rats, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.